Home / Intelligence / Blog / Developing Effective Global Value Dossiers
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level of detail and more. Regional affiliates were also interviewed to understand what they liked and what they found challenging about the GVDs.
Identifying Key Areas for Improvement
The team discovered that while the mechanics of GVD creation were usually well done, affiliates struggled to find the regional data most relevant to them and GVDs did not always help users see the strategic thread between different sections.
Developing a GVD Best Practice Toolkit
To address these challenges, Trinity developed a GVD best practice toolkit that provided guidance on how to write each chapter of the GVD. The toolkit also included several checklists and practical tools. These included a schematic showing what each stakeholder in the cross-functional team was responsible for and by when, as well as a mapping of drivers and evidence requirements for each country and checklists for each stage of the process.
Overcoming Challenges in GVD Development
Our analysis of GVDs across many therapy areas found that one challenge that teams frequently encounter is presenting a cogent economic story that aligns with the overall strategic goals of the GVD while also being practical and tactical.
The process developed by Trinity was designed to flex to different needs in different markets while maintaining consistency in how evidence is portrayed and messaged.
Conclusion and Call to Action
Overall, the project demonstrated the value of taking an independent view of GVD development and incorporating feedback from regional affiliates to create a more effective and streamlined process. If your company needs help with GVD development, Trinity’s Value Center of Excellence can provide guidance and support. Contact us to learn more.
Meet Our Experts
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now